Natixis Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.36M | Buy |
47,115
+606
| +1% | +$17.4K | ﹤0.01% | 1205 |
|
|
2025
Q1 | $1.56M | Buy |
46,509
+826
| +2% | +$27.7K | ﹤0.01% | 1155 |
|
|
2024
Q4 | $2.34M | Buy |
45,683
+1,337
| +3% | +$68.4K | ﹤0.01% | 1048 |
|
|
2024
Q3 | $2.27M | Buy |
44,346
+11,870
| +37% | +$607K | ﹤0.01% | 1056 |
|
|
2024
Q2 | $1.46M | Buy |
32,476
+5,052
| +18% | +$226K | ﹤0.01% | 1147 |
|
|
2024
Q1 | $1.28M | Buy |
27,424
+1,883
| +7% | +$88.2K | ﹤0.01% | 1151 |
|
|
2023
Q4 | $908K | Sell |
25,541
-89
| -0.3% | -$3.16K | ﹤0.01% | 1232 |
|
|
2023
Q3 | $762K | Buy |
25,630
+5,243
| +26% | +$156K | ﹤0.01% | 1241 |
|
|
2023
Q2 | $367K | Buy |
20,387
+165
| +0.8% | +$2.97K | ﹤0.01% | 1400 |
|
|
2023
Q1 | $325K | Buy |
20,222
+8,458
| +72% | +$136K | ﹤0.01% | 1399 |
|
|
2022
Q4 | $215K | Sell |
11,764
-84
| -0.7% | -$1.54K | ﹤0.01% | 1435 |
|
|
2022
Q3 | $233K | Sell |
11,848
-29
| -0.2% | -$570 | ﹤0.01% | 1422 |
|
|
2022
Q2 | $222K | Buy |
+11,877
| New | +$222K | ﹤0.01% | 1439 |
|